Diarylquinolines target subunit c of mycobacterial ATP synthase
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The diarylquinoline R207910 (TMC207) is a promising candidate in clinical development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear mutations in ATP synthase, the compound's precise target is not known. Here we establish by genetic, biochemical and binding assays that the oligomeric subunit c (AtpE) of ATP synthase is the target of R207910. Thus targeting energy metabolism is a new, promising approach for antibacterial drug discovery.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [111]
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationMolecular mechanisms that confer antibacterial drug resistance
Walsh, C. (2000) · Nature · doi:10.1038/35021219 · Cited by 1,578
The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol
Telenti, A., Philipp, W. J., Sreevatsan, S., Bernasconi, C., Stockbauer, K. E., Wieles, B., Musser, J. M., & Jacobs, W. R. (1997) · Nature Medicine · doi:10.1038/nm0597-567 · Cited by 472
Telenti, A., Honoré, N., Bernasconi, C., March, J., Ortega, A., Heym, B., Takiff, H. E., & Cole, S. T. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.719-723.1997 · Cited by 320
de Jonge, M. R., Koymans, L. H. M., Guillemont, J. E. G., Koul, A., & Andries, K. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21376 · Cited by 124
Self-citationThe F 1 F o -ATP Synthase of Mycobacterium smegmatis Is Essential for Growth
Tran, S. L., & Cook, G. M. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.14.5023-5028.2005 · Cited by 116
Ji, B., Lefrançois, S., Robert, J., Chauffour, A., Truffot-Pernot, C., & Jarlier, V. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00052-06 · Cited by 107
Wang, R., Prince, J. T., & Marcotte, E. M. (2005) · Genome Research · doi:10.1101/gr.3994105 · Cited by 86
Junge, W., & Nelson, N. (2005) · Science · doi:10.1126/science.1112617 · Cited by 60
Cited by
The challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
Self-citationAdvances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
Self-citationAntibiotic efficacy is linked to bacterial cellular respiration
Lobritz, M. A., Belenky, P., Porter, C. B. M., Gutierrez, A., Yang, J. H., Schwarz, E. G., Dwyer, D. J., Khalil, A. S., & Collins, J. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509743112 · Cited by 773
Almeida Da Silva, P. E., & Palomino, J. C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr173 · Cited by 532
Rao, S. P. S., Alonso, S., Rand, L., Dick, T., & Pethe, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711697105 · Cited by 517
Cadena, A. M., Fortune, S. M., & Flynn, J. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.69 · Cited by 484
Drug Resistance Mechanisms in Mycobacterium tuberculosis
Palomino, J., & Martin, A. (2014) · Antibiotics · doi:10.3390/antibiotics3030317 · Cited by 442
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Andries, K., Villellas, C., Coeck, N., Thys, K., Gevers, T., Vranckx, L., Lounis, N., de Jong, B. C., & Koul, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102135 · Cited by 439
Self-citationAntibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Alsayed, S. S. R., & Gunosewoyo, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065202 · Cited by 332
Prospects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 372
Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Göhlmann, H. W. H., Willebrords, R., Poncelet, A., Guillemont, J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803899200 · Cited by 364
Self-citationNew agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 328
History of antimicrobial drug discovery: Major classes and health impact
Aminov, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.001 · Cited by 296
Quinoline: A promising antitubercular target
Keri, R. S., & Patil, S. A. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.10.007 · Cited by 301
Hong, S., & Pedersen, P. L. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00016-08 · Cited by 301
Lilienkampf, A., Mao, J., Wan, B., Wang, Y., Franzblau, S. G., & Kozikowski, A. P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900003c · Cited by 308
Preiss, L., Langer, J. D., Yildiz, Ö., Eckhardt-Strelau, L., Guillemont, J. E. G., Koul, A., & Meier, T. (2015) · Science Advances · doi:10.1126/sciadv.1500106 · Cited by 293
Self-citationKoul, A., Vranckx, L., Dhar, N., Göhlmann, H. W. H., Özdemir, E., Neefs, J.-M., Schulz, M., Lu, P., Mørtz, E., McKinney, J. D., et al. (2014) · Nature Communications · doi:10.1038/ncomms4369 · Cited by 293
Self-citationRustomjee, R., Diacon, A. H., Allen, J., Venter, A., Reddy, C., Patientia, R. F., Mthiyane, T. C. P., De Marez, T., van Heeswijk, R., Kerstens, R., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01204-07 · Cited by 278
Self-citationAntibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
VanderVen, B. C., Fahey, R. J., Lee, W., Liu, Y., Abramovitch, R. B., Memmott, C., Crowe, A. M., Eltis, L. D., Perola, E., Deininger, D. D., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004679 · Cited by 263
Gengenbacher, M., Rao, S. P. S., Pethe, K., & Dick, T. (2010) · Microbiology · doi:10.1099/mic.0.033084-0 · Cited by 260
Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis
Sacchettini, J. C., Rubin, E. J., & Freundlich, J. S. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1816 · Cited by 256
Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis
Ioerger, T. R., O’Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075245 · Cited by 241
Bedaquiline: a review of human pharmacokinetics and drug-drug interactions
van Heeswijk, R. P. G., Dannemann, B., & Hoetelmans, R. M. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku171 · Cited by 236
Bactericidal mode of action of bedaquiline
Hards, K., Robson, J. R., Berney, M., Shaw, L., Bald, D., Koul, A., Andries, K., & Cook, G. M. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv054 · Cited by 226
Self-citationHaagsma, A. C., Abdillahi-Ibrahim, R., Wagner, M. J., Krab, K., Vergauwen, K., Guillemont, J., Andries, K., Lill, H., Koul, A., & Bald, D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01393-08 · Cited by 221
Self-citationBald, D., Villellas, C., Lu, P., & Koul, A. (2017) · mBio · doi:10.1128/mbio.00272-17 · Cited by 219
Self-citationCook, G. M., Berney, M., Gebhard, S., Heinemann, M., Cox, R. A., Danilchanka, O., & Niederweis, M. (2009) · Advances in Microbial Physiology · doi:10.1016/s0065-2911(09)05502-7 · Cited by 204
Almeida, D., Ioerger, T., Tyagi, S., Li, S.-Y., Mdluli, K., Andries, K., Grosset, J., Sacchettini, J., & Nuermberger, E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00753-16 · Cited by 209
Self-citationHuitric, E., Verhasselt, P., Koul, A., Andries, K., Hoffner, S., & Andersson, D. I. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01611-09 · Cited by 215
Self-citationBedaquiline Resistance: Its Emergence, Mechanism, and Prevention
Nguyen, T. V. A., Anthony, R. M., Bañuls, A.-L., Nguyen, T. V. A., Vu, D. H., & Alffenaar, J.-W. C. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix992 · Cited by 203
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T., & Berney, M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0015-2013 · Cited by 212
“Research into mycobacterial respiration and oxidative phosphorylation has been energized by the discovery of a new drug (TMC207; Sirturo; Bedaquiline) that targets the ATP synthase of mycobacteria, suggesting that inhibitors of respiration and ATP synthesis will provide the next generation of front-line drugs to comba…”
BackgroundInfluentialTmc207: the First Compound of A New class of Potent Anti-Tuberculosis Drugs
Matteelli, A., Carvalho, A. C., Dooley, K. E., & Kritski, A. (2010) · Future Microbiology · doi:10.2217/fmb.10.50 · Cited by 204
Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline
Guo, H., Courbon, G. M., Bueler, S. A., Mai, J., Liu, J., & Rubinstein, J. L. (2021) · Nature · doi:10.1038/s41586-020-3004-3 · Cited by 200
Targeting Bacterial Central Metabolism for Drug Development
Murima, P., McKinney, J. D., & Pethe, K. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.020 · Cited by 189
Survey of the year 2007 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2008) · Journal of Molecular Recognition · doi:10.1002/jmr.928 · Cited by 178
Tuberculosis: The drug development pipeline at a glance
Villemagne, B., Crauste, C., Flipo, M., Baulard, A. R., Déprez, B., & Willand, N. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.02.033 · Cited by 172
Hameed, H. M. A., Islam, M. M., Chhotaray, C., Wang, C., Liu, Y., Tan, Y., Li, X., Tan, S., Delorme, V., Yew, W. W., et al. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00114 · Cited by 175
An overview of new antitubercular drugs, drug candidates, and their targets
Bahuguna, A., & Rawat, D. S. (2020) · Medicinal Research Reviews · doi:10.1002/med.21602 · Cited by 170
Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052951 · Cited by 177
“identified utilizing a whole cell phenotypic HTS campaign of a library of more than 70,000 compounds against Mycobacterium smegmatis [11,12,13].”
MethodIn Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor
Huitric, E., Verhasselt, P., Andries, K., & Hoffner, S. E. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00181-07 · Cited by 172
Self-citationLunde, C. S., Hartouni, S. R., Janc, J. W., Mammen, M., Humphrey, P. P., & Benton, B. M. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01710-08 · Cited by 170
Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier
Rhee, K. Y., Carvalho, L. P. S. D., Bryk, R., Ehrt, S., Marrero, J., Park, S. W., Schnappinger, D., Venugopal, A., & Nathan, C. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.03.008 · Cited by 164
Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence
Pontali, E., Sotgiu, G., D’Ambrosio, L., Centis, R., & Migliori, G. B. (2016) · European Respiratory Journal · doi:10.1183/13993003.01891-2015 · Cited by 159
Energy Metabolism and Drug Efflux in Mycobacterium tuberculosis
Black, P. A., Warren, R. M., Louw, G., van Helden, P. D., Victor, T. C., & Kana, B. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02293-13 · Cited by 172
Cholo, M. C., Mothiba, M. T., Fourie, B. P., & Anderson, R. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw426 · Cited by 158
Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion
Johnson, J. L., Hadad, D. J., Dietze, R., Maciel, E. L. N., Sewali, B. P., Gitta, P., Okwera, A., Mugerwa, R. D., Alcaneses, M. R., Quelapio, M. I., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0536oc · Cited by 147
Dhiman, R. K., Mahapatra, S., Slayden, R. A., Boyne, M. E., Lenaerts, A., Hinshaw, J. C., Angala, S. K., Chatterjee, D., Biswas, K., Narayanasamy, P., et al. (2009) · Molecular Microbiology · doi:10.1111/j.1365-2958.2009.06625.x · Cited by 146
“However, as the K vitamins rescue both growth and oxygen consumption at Ro 48-8071 concentrations several fold higher than its MIC (Fig.”
BackgroundInfluentialProbing the Interaction of the Diarylquinoline TMC207 with Its Target Mycobacterial ATP Synthase
Haagsma, A. C., Podasca, I., Koul, A., Andries, K., Guillemont, J., Lill, H., & Bald, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023575 · Cited by 149
Self-citationNew anti-tuberculosis drugs in clinical trials with novel mechanisms of action
Rivers, E. C., & Mancera, R. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.004 · Cited by 141
Diagnosis and treatment of multidrug-resistant tuberculosis
Jang, J. G., & Chung, J. H. (2020) · Yeungnam University Journal of Medicine · doi:10.12701/yujm.2020.00626 · Cited by 140
“Bedaquiline is a diarylquinoline compound that specifically inhibits the adenosine triphosphate synthase by blocking the flow of mycobacterial proton pump [47].”
BackgroundCook, G. M., Hards, K., Dunn, E. A., Heikal, A., Nakatani, Y., Greening, C., Crick, D. C., Fontes, F. L., Pethe, K., Hasenoehrl, E., et al. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0014-2016 · Cited by 141
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
Svensson, E. M., Murray, S. R., Karlsson, M. O., & Dooley, K. E. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku504 · Cited by 130
Antituberculosis Drug Research: A Critical Overview
Beena, & Rawat, D. S. (2012) · Medicinal Research Reviews · doi:10.1002/med.21262 · Cited by 139
Energetics of Pathogenic Bacteria and Opportunities for Drug Development
Cook, G. M., Greening, C., Hards, K., & Berney, M. (2014) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2014.08.001 · Cited by 147
Tantry, S. J., Markad, S. D., Shinde, V. N., Bhat, J., Balakrishnan, G., Gupta, A. K., Ambady, A., Raichurkar, A. V., Kedari, C. K., Sharma, S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01358 · Cited by 131
A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
Fox, G. J., & Menzies, D. (2013) · Infectious Diseases and Therapy · doi:10.1007/s40121-013-0009-3 · Cited by 134
Dupont, C., Viljoen, A. J., Thomas, S. S., Roquet, F., Herrmann, J., Pethe, K., & Kremer, L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01225-17 · Cited by 126
Lu, P., Heineke, M. H., Koul, A., Andries, K., Cook, G. M., Lill, H., van Spanning, R., & Bald, D. (2015) · Scientific Reports · doi:10.1038/srep10333 · Cited by 119
Self-citationMak, P. A., Rao, S. P. S., Tan, M. P., Lin, X., Chyba, J., Tay, J. A., Ng, S. H., Tan, B. H., Cherian, J., Duraiswamy, J., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb2004884 · Cited by 126
Ismail, N. A., Omar, S. V., Joseph, L., Govender, N., Blows, L., Ismail, F., KOORNHOF, H. J., Dreyer, A. W., Kaniga, K., & Ndjeka, N. O. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.005 · Cited by 121
Borisov, V. B., Siletsky, S. A., Paiardini, A., Hoogewijs, D., Forte, E., Giuffrè, A., & Poole, R. K. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8039 · Cited by 121
Mycobacterium tuberculosis : immune response, biomarkers, and therapeutic intervention
Li, Z., Yang, L., Li, L., Ye, Z., & Gong, W. (2024) · MedComm · doi:10.1002/mco2.419 · Cited by 144
Grosset, J. H. E., Singer, T. G., & Bishai, W. R. (2012) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.12.0277 · Cited by 128
Sutherland, H. S., Tong, A. S. T., Choi, P. J., Blaser, A., Conole, D., Franzblau, S. G., Lotlikar, M. U., Cooper, C. B., Upton, A. M., Denny, W. A., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.026 · Cited by 119
Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm : Figure 1.
Chakraborty, S., & Rhee, K. Y. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021147 · Cited by 144
Rouan, M. C., Lounis, N., Gevers, T., Dillen, L., Gilissen, R., Raoof, A. A., & Andries, K. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00720-11 · Cited by 116
Self-citationATP synthase in mycobacteria: Special features and implications for a function as drug target
Lü, P., Lill, H., & Bald, D. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.01.022 · Cited by 130
Self-citationMandewale, M. C., Patil, U., Shedge, S. V., Dappadwad, U. R., & Yamgar, R. (2017) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1016/j.bjbas.2017.07.005 · Cited by 114
The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection
Giraud-Gatineau, A., Coya, J. M., Maure, A., Biton, A., Thomson, M., Bernard, E. M., Marrec, J., Gutierrez, M. G., Larrouy-Maumus, G. J., Brosch, R., et al. (2020) · eLife · doi:10.7554/elife.55692 · Cited by 120
Ejalonibu, M. A., Ogundare, S. A., El-Rashedy, A. A. E., Ejalonibu, M. A., Lawal, M. M., Mhlongo, N. N., & Kumalo, H. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413259 · Cited by 122
Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents
Bangalore, P. K., Vagolu, S. K., Bollikanda, R. K., Veeragoni, D. K., Choudante, P. C., Misra, S., Sriram, D., Sridhar, B., & Kantevari, S. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00475 · Cited by 106
Drugs in Development for Tuberculosis
Ginsberg, A. M. (2010) · Drugs · doi:10.2165/11538170-000000000-00000 · Cited by 113
Richard, M., Gutiérrez, A. V., Viljoen, A. J., Rodriguez-Rincon, D., Roquet, F., Blaise, M., Everall, I., Parkhill, J., Floto, R. A., & Kremer, L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01316-18 · Cited by 106
Haagsma, A. C., Driessen, N. N., Hahn, M.-M., Lill, H., & Bald, D. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.02123.x · Cited by 98
Self-citationF1F0-ATP synthases of alkaliphilic bacteria: Lessons from their adaptations
Hicks, D. B., Liu, J., Fujisawa, M., & Krulwich, T. A. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.02.028 · Cited by 94
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
Field, S. K. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315582325 · Cited by 111
Targeting bacterial energetics to produce new antimicrobials
Hards, K., & Cook, G. M. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.11.001 · Cited by 113
Guillemont, J., Meyer, C., Poncelet, A., Bourdrez, X., & Andries, K. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.79 · Cited by 101
Self-citationChallenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis
Machado, D., Girardini, M., Viveiros, M., & Pieroni, M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01367 · Cited by 106
Svensson, E. M., Aweeka, F. T., Park, J., Marzan, F., Dooley, K. E., & Karlsson, M. O. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00191-13 · Cited by 98
Novel Antibiotics Targeting Respiratory ATP Synthesis in Gram-Positive Pathogenic Bacteria
Balemans, W., Vranckx, L., Lounis, N., Pop, O. I., Guillemont, J., Vergauwen, K., Mol, S., Gilissen, R., Motte, M., Lançois, D., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00273-12 · Cited by 103
Self-citationBedaquiline – The first ATP synthase inhibitor against multi drug resistant tuberculosis
Lakshmanan, M., & Xavier, A. S. (2013) · Journal of Young Pharmacists · doi:10.1016/j.jyp.2013.12.002 · Cited by 103
Genetic requirements for Staphylococcus aureus nitric oxide resistance and virulence
Grosser, M. R., Paluscio, E., Thurlow, L. R., Dillon, M. M., Cooper, V. S., Kawula, T. H., & Richardson, A. R. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1006907 · Cited by 91
Alexander, D. C., Vasireddy, R., Vasireddy, S., Philley, J. V., Brown‐Elliott, B. A., Perry, B. J., Griffith, D. E., Benwill, J. L., Cameron, A. D. S., & Wallace, R. J. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02087-16 · Cited by 93
Lü, P., Asseri, A. H., Kremer, M., Maaskant, J. J., Ummels, R., Lill, H., & Bald, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-20989-8 · Cited by 98
Self-citationIonophoric effects of the antitubercular drug bedaquiline
Hards, K., McMillan, D. G. G., Schurig-Briccio, L. A., Gennis, R. B., Lill, H., Bald, D., & Cook, G. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803723115 · Cited by 95
Self-citationTargeting the Proteostasis Network for Mycobacterial Drug Discovery
Lupoli, T. J., Vaubourgeix, J., Burns-Huang, K. E., & Gold, B. S. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00231 · Cited by 94
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
Sturkenboom, M. G. G., Märtson, A., Svensson, E. M., Sloan, D. J., Dooley, K. E., van den Elsen, S. H. J., Denti, P., Peloquin, C. A., Aarnoutse, R. E., & Alffenaar, J. C. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-00997-0 · Cited by 96
Machado, D., Pires, D., Perdigão, J., Couto, I., Portugal, I., Martins, M., Amaral, L., Anes, E., & Viveiros, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149326 · Cited by 101
Tuberculous meningitis: The challenges
Murthy, J. M. K. (2010) · Neurology India · doi:10.4103/0028-3886.72178 · Cited by 100
Respiratory ATP synthesis: the new generation of mycobacterial drug targets?
Bald, D., & Koul, A. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.01959.x · Cited by 94
Self-citationKrishna, K. M., Inturi, B., Pujar, G. V., Purohit, M. N., & Vijaykumar, G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.051 · Cited by 87
Svensson, E., Dosne, A., & Karlsson, M. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12147 · Cited by 90
Dooley, K. E., Park, J., Swindells, S., Allen, R., Haas, D. W., Cramer, Y. S., Aweeka, F. T., Wiggins, I. P., Gupta, A., Lizak, P. S., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182410503 · Cited by 86
Rising to the challenge: new therapies for tuberculosis
Wong, E. B., Cohen, K. A., & Bishai, W. R. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.05.002 · Cited by 87
Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline
Sarathy, J. P., Grüber, G., & Dick, T. (2019) · Antibiotics · doi:10.3390/antibiotics8040261 · Cited by 97
Metadata
- Authors
- Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., Bald, D., & Andries, K.
- Affiliations
- Johnson & Johnson (United States) (US)
- Vrije Universiteit Amsterdam (NL)
- Johnson & Johnson (France) (FR)
- Corresponding author
- Koul, Anil
- Venue
- Nature Chemical Biology
- Published
- 2007-05-13
- Volume
- 3
- Issue
- 6
- Pages
- 323-324
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2093364655
- Cited by
- 547
- References
- 11
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 27 · 2023: 27 · 2022: 40 · 2021: 50 · 2020: 31 · 2019: 40 · 2018: 36 · 2017: 40 · 2016: 23 · 2015: 33 · 2014: 26 · 2013: 31 · 2012: 22
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- diarylquinolines, bedaquiline, subunit c, atpE, tuberculosis, drug target identification, drug resistance, energy metabolism, antibiotic discovery
- MeSH terms
- Antitubercular Agents, Bacterial Proteins, Binding Sites, Kinetics, Quinolines, Electrophoresis, Gel, Two-Dimensional, Mycobacterium smegmatis, Protein Subunits, ATP Synthetase Complexes, Bacterial Proton-Translocating ATPases, Diarylquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.